Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 13.7%

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 3,020,000 shares, a decrease of 13.7% from the September 15th total of 3,500,000 shares. Based on an average daily trading volume, of 346,000 shares, the days-to-cover ratio is currently 8.7 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Oppenheimer assumed coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective on the stock. Bank of America decreased their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Truist Financial reiterated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday. They set a “sector outperform” rating for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $90.63.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics during the second quarter valued at approximately $1,118,000. Bank of New York Mellon Corp boosted its holdings in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares in the last quarter. Swiss National Bank grew its position in Keros Therapeutics by 22.0% in the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $3,303,000 after buying an additional 9,000 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Keros Therapeutics in the second quarter valued at $532,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 0.1 %

Keros Therapeutics stock traded down $0.04 during trading hours on Wednesday, hitting $60.35. 7,890 shares of the company traded hands, compared to its average volume of 369,823. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The firm has a market cap of $2.18 billion, a P/E ratio of -11.73 and a beta of 1.23. The firm’s 50-day simple moving average is $52.45 and its two-hundred day simple moving average is $52.01.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter last year, the firm posted ($1.27) earnings per share. On average, equities research analysts predict that Keros Therapeutics will post -4.88 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.